Prexton Therapeutics BV (Oss, the Netherlands and Geneva, Switzerland) develops innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders.
Prexton’s lead compound Foliglurax is a novel mGluR4 compound currently in clinical development for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (involuntary muscle movements).
In 2015, Sunstone Capital, through its Sunstone Life Science Fund III, joined the Series A financing of Prexton as a Co-Lead investor and was represented on the Board since then, supporting the company in strategic and operational matters.
In March 2018, Prexton was sold to H. Lundbeck A/S (Lundbeck). Under the terms of the agreement Lundbeck has paid €100 million in cash upfront to Prexton’s former shareholders and is furthermore required to pay additional €805 million in development, regulatory and sales milestones depending on successful outcome of certain undisclosed milestones.
For more information please contact:
Phone +45 2481 6967